Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

KENILWORTH, N.J., April 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy will be presented at the European Association for the Study of the Liver (EASL) 43rd annual meeting in Milan, Italy, April 23-27. PEGINTRON combination therapy is a current standard of care in the treatment of chronic hepatitis C. A total of 36 data presentations, including nine oral presentations, highlighting Schering-Plough hepatitis medications will be presented at EASL 2008.

The IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimaL pegylated interferon therapy) study is the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON and REBETOL combination therapy vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination therapy,(1) as well as a lower dose of PEGINTRON plus REBETOL in an investigational combination regimen. Pegasys and Copegus were dosed in accordance with their approved U.S. labeling in this study of more than 3,000 U.S. genotype 1 patients. Results showed that sustained virologic response (SVR), the primary endpoint of the study, was similar for all three treatment regimens. The study also showed in a secondary endpoint that fewer patients treated with both PEGINTRON regimens relapsed after the end of treatment compared to those receiving Pegasys and Copegus.

Final results will be presented for the EPIC3 study, in which more than 2,000 hepatit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)...  Becton, Dickinson and Company (NYSE: BDX ) ... exchange all validly tendered and accepted notes of the ... subsidiary of BD, for notes to be issued by ... Statement on Form S-4 (the "Registration Statement") relating to ... the Securities and Exchange Commission ("SEC") on March 26, ...
(Date:3/26/2015)... , March 26, 2015  An Ohio entrepreneur is ... own medical records.  As CEO for a start-up company known ... is launching a new business that will empower individuals to ... leap over today,s insecure methods. ... of Encrypted Data – will enable people to protect their ...
(Date:3/26/2015)... Illinois , 26. März 2015 /PRNewswire/ ... (NABP®) wird vom 1. April 2015 an Zulassungsanträge ... allen abgebenden Apotheken annehmen. Seit dem Start ... der Verband über 275 .pharmacy-Domainnamen zugelassen, die ... dieser Zeiten beantragt wurden. Die NABP startete ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 2Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 3Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 4Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... 27, 2015 The Thomas ... philanthropic, grant-making foundation committed to raising its voice ... is delivered. , The Scattergood Foundation and The ... Health Policy and Practice through the Annual Scattergood ... Program App is designed to guide the IBS ...
(Date:3/26/2015)... Dr. Rod J. Rohrich, who served as ... and has trained over 6500 surgeons through these meetings ... medicine (EBM), that is, the optimization of decision making ... often hear from rhinoplasty surgeons who describe ... not trying to stifle these discussions, we do want ...
(Date:3/26/2015)... 2015 The American College of Traditional Chinese ... topics of the DAOM Program as well as Marketing Basics ... will be hosted by Dr. Carla Wilson, who will give ... on how to prepare for the spring quarter. The webinar ... 27, April 1 and April 3. Attendees can log in ...
(Date:3/26/2015)... 26, 2015 The Baruch S. Blumberg ... of nationally renowned scientists to focus exclusively on research ... that nearly triples its research capacity and has created ... hepatitis B and liver cancer in the United States. ... Chang, Ju Tao Guo and Ying-Hsiu Su – and ...
Breaking Medicine News(10 mins):Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:ACTCM Announces Upcoming Webinars 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4
... Maureen Salamon HealthDay Reporter , TUESDAY, April ... and coordination that Parkinson,s patients struggle with might ... a different approach to exercise, researchers suggest. Parkinson,s ... mobility from lengthy, low-intensity training such as brisk walking, ...
... Bacterial genes that make urine less acidic could be ... presented at the Society for General Microbiology,s Spring Conference ... to prevent serious infections, particularly in long-term catheterization patients. ... community care homes to manage a range of bladder ...
... TUESDAY, April 12 (HealthDay News) -- Eating apples every day ... Women who ate dried apples every day for a ... levels of "bad" LDL cholesterol by 23 percent. "I ... extent while increasing HDL cholesterol or good cholesterol by about ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... transmit the virus to partners even when they do not ... suspected before, "the data here looks really robust," said Fred ... Herpes simplex virus type 2 (HSV-2) infection is one ...
... April 12 (HealthDay News) -- Moderate aerobic exercise helps boost blood ... The small study included 16 women aged 60 and older who ... a week for three months. By the end of that time, ... as much as 15 percent. The researchers also found that ...
... (April 12, 2011) Fatih Uckun, MD, PhD, head of ... for Cancer and Blood Diseases at Children,s Hospital Los Angeles, ... of Medicine of the University of Southern California, has been ... support development of a new strategy to overcome the resistance ...
Cached Medicine News:Health News:Low-Intensity Exercise, Drug Combo Can Help Parkinson's Patients, Studies Show 2Health News:Low-Intensity Exercise, Drug Combo Can Help Parkinson's Patients, Studies Show 3Health News:Potential new strategy to reduce catheter blockage 2Health News:An Apple a Day May Help Keep Heart Disease Away 2Health News:An Apple a Day May Help Keep Heart Disease Away 3Health News:Genital Herpes Can Be Spread When Lesions Aren't Present: Study 2Health News:Brisk Walk Can Boost Blood Flow to the Brain: Report 2Health News:NCI awards $1.7 million to cancer specialist at Children's Hospital Los Angeles 2
... ventilated microcentrifuge combines powerful, quiet performance with attractive, ... that gives you maximum value...MORE for LESS., ... to 17,000 xg at speeds of 13,500 rpm ... mL) microtubes., More Features , Microlite ...
... single rotation speed of 10,000 rpm , ... , Pellets single- and double-stranded DNA , ... , 12-position rotor holds 0.5-ml microcentrifuge tubes ... , Replaceable rotor , Safety ...
... The Centrifuge 4-15C is designed to accommodate ... provide the necessary force of more than 5600 ... wide range of both fixed-angle and swing-out rotors ... 5 ml, 15 ml, and 50 ml tubes, ...
... High performance Model 5417 C spins up to ... model offers unsurpassed safety, reliability, and ease of use. ... the lab bench or in a cold room and ... application range., Product features , Spin up ...
Medicine Products: